3D Spheroid Configurations Are Possible Indictors for Evaluating the Pathophysiology of Melanoma Cell Lines.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
27 02 2023
Historique:
received: 13 12 2022
revised: 24 02 2023
accepted: 26 02 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 15 3 2023
Statut: epublish

Résumé

To study the molecular mechanisms responsible for inducing the spatial proliferation of malignant melanomas (MM), three-dimension (3D) spheroids were produced from several MM cell lines including SK-mel-24, MM418, A375, WM266-4, and SM2-1, and their 3D architectures and cellular metabolisms were evaluated by phase-contrast microscopy and Seahorse bio-analyzer, respectively. Several transformed horizontal configurations were observed within most of these 3D spheroids, and the degree of their deformity was increased in the order: WM266-4, SM2-1, A375, MM418, and SK-mel-24. An increased maximal respiration and a decreased glycolytic capacity were observed within the lesser deformed two MM cell lines, WM266-4 and SM2-1, as compared with the most deformed ones. Among these MM cell lines, two distinct cell lines, WM266-4 and SK-mel-24, whose 3D appearances were the closest and farthest, respectively, from being horizontally circular-shaped, were subjected to RNA sequence analyses. Bioinformatic analyses of the differentially expressed genes (DEGs) identified KRAS and SOX2 as potential master regulatory genes for inducing these diverse 3D configurations between WM266-4 and SK-mel-24. The knockdown of both factors altered the morphological and functional characteristics of the SK-mel-24 cells, and in fact, their horizontal deformity was significantly reduced. A qPCR analysis indicated that the levels of several oncogenic signaling related factors, including KRAS and SOX2, PCG1α, extracellular matrixes (ECMs), and ZO1 had fluctuated among the five MM cell lines. In addition, and quite interestingly, the dabrafenib and trametinib resistant A375 (A375DT) cells formed globe shaped 3D spheroids and showed different profiles in cellular metabolism while the mRNA expression of these molecules that were tested as above were different compared with A375 cells. These current findings suggest that 3D spheroid configuration has the potential for serving as an indicator of the pathophysiological activities associated with MM.

Identifiants

pubmed: 36899895
pii: cells12050759
doi: 10.3390/cells12050759
pmc: PMC10000690
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Signal Transduct Target Ther. 2020 Jul 29;5(1):135
pubmed: 32728033
Cell. 2019 Jan 10;176(1-2):98-112.e14
pubmed: 30633912
Cell. 2018 May 31;173(6):1413-1425.e14
pubmed: 29754815
Healthcare (Basel). 2013 Dec 23;2(1):27-46
pubmed: 27429258
Br J Dermatol. 2017 Jul;177(1):134-140
pubmed: 28369739
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209601
Cancer Cell. 2021 May 10;39(5):610-631
pubmed: 33545064
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Int J Mol Sci. 2021 Jul 08;22(14):
pubmed: 34298955
Lab Chip. 2019 Jan 29;19(3):369-386
pubmed: 30644496
Cells. 2022 Jan 16;11(2):
pubmed: 35053416
Nat Cancer. 2021 Mar;2(3):271-283
pubmed: 33870211
Front Oncol. 2018 May 24;8:173
pubmed: 29881716
Endocrinology. 2019 Jan 1;160(1):20-35
pubmed: 30388216
Sci Rep. 2020 May 14;10(1):7958
pubmed: 32409724
Biomedicines. 2021 Jul 31;9(8):
pubmed: 34440134
Oncotarget. 2019 Mar 1;10(18):1662-1663
pubmed: 30899437
Pigment Cell Melanoma Res. 2012 Jul;25(4):533-6
pubmed: 22571403
Methods Mol Biol. 2017;1566:177-183
pubmed: 28244051
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Exp Med. 1999 Aug 2;190(3):355-66
pubmed: 10430624
Mol Cell Endocrinol. 2017 Aug 15;451:1-14
pubmed: 28576744
Exp Physiol. 2017 Mar 1;102(3):291-298
pubmed: 28087888
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Exp Dermatol. 2018 May;27(5):578-586
pubmed: 29697862
J Clin Oncol. 2013 Feb 1;31(4):482-9
pubmed: 23248257
Elife. 2021 Jan 13;10:
pubmed: 33438577
Swiss Med Wkly. 2019 Apr 04;149:w20057
pubmed: 30946479
PLoS One. 2014 May 27;9(5):e98250
pubmed: 24866829
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
Cell. 1993 Jul 30;74(2):395-404
pubmed: 8343963
Trends Cell Biol. 2011 Dec;21(12):745-54
pubmed: 22033488
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Cancers (Basel). 2020 Jan 03;12(1):
pubmed: 31947710
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
PeerJ. 2021 Nov 19;9:e12452
pubmed: 34820188
Cell. 2007 Aug 24;130(4):601-10
pubmed: 17719539
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Front Oncol. 2015 Jun 08;5:121
pubmed: 26106584
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Pathobiology. 1999 May-Jun;67(3):148-57
pubmed: 10394136
Science. 2014 Nov 21;346(6212):945-9
pubmed: 25414302
Biomaterials. 2018 May;165:105-120
pubmed: 29525264
J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):68-75
pubmed: 22265957
Int J Cancer. 2018 Dec 15;143(12):3131-3142
pubmed: 29905375
Biochem J. 2000 Oct 15;351 Pt 2:289-305
pubmed: 11023813
Oncotarget. 2017 Nov 14;8(64):107977-107990
pubmed: 29296217
Genes Dev. 2018 Sep 1;32(17-18):1175-1187
pubmed: 30135074
Signal Transduct Target Ther. 2020 Oct 30;5(1):249
pubmed: 33122631
Front Bioeng Biotechnol. 2016 Feb 12;4:12
pubmed: 26904541
Acta Pharmacol Sin. 2019 Feb;40(2):268-278
pubmed: 29777202
Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92
pubmed: 22578220
Expert Opin Drug Discov. 2019 Mar;14(3):289-301
pubmed: 30689452
JAMA. 2011 Jun 8;305(22):2327-34
pubmed: 21642685
Nat Commun. 2020 Jun 5;11(1):2858
pubmed: 32504051
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Front Immunol. 2020 Dec 10;11:603640
pubmed: 33362787
Cancer Res. 2017 Apr 15;77(8):1955-1967
pubmed: 28209618
Mediators Inflamm. 2021 Jun 14;2021:9918379
pubmed: 34220337
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6
pubmed: 9843973
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936

Auteurs

Hiroshi Ohguro (H)

Departments of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Megumi Watanabe (M)

Departments of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Tatsuya Sato (T)

Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.
Departments of Cellular Physiology and Signal Transduction, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Fumihito Hikage (F)

Departments of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Masato Furuhashi (M)

Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Masae Okura (M)

Departments of Dermatology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Tokimasa Hida (T)

Departments of Dermatology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Hisashi Uhara (H)

Departments of Dermatology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH